MFG
BCRX icon

Merit Financial Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Merit Financial Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$192K Buy
+19,185
New +$173K ﹤0.01% 2131
2025
Q2 		– Sell
-13,360
Closed -$100K – 1703
2025
Q1 		$100K Buy
+13,360
New +$108K ﹤0.01% 1357

Other funds holding BCRX

WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
MBI
May Barnhard Investments Bethesda, Maryland $247M AUM 24.53% 1-Year Est. Return
CWS
Cypress Wealth Services Palm Desert, California $815M AUM 27.86% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Merit Financial Group's BCRX Position: Q2 2026 in Review

Merit Financial Group opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 19,185 shares worth $192K. The stake represents ﹤0.01% of the portfolio and ranks #2131 among its holdings. This is a return to the name: Merit Financial Group previously reported a position in BCRX as recently as Q1 2025.

Merit Financial Group first reported a position in BCRX in Q1 2025 and has held it in 2 quarters since. 25 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Merit Financial Group held 19,185 shares of BioCryst Pharmaceuticals worth $192K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Merit Financial Group position in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #2131 holding.
  • Merit Financial Group first reported a position in BioCryst Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • 25 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.